Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells

Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells

ABCB1 overexpression is known to contribute to multidrug resistance (MDR) in cancers. Therefore, it is critical to find effective drugs to target ABCB1 and overcome MDR. Erdafitinib is a tyrosine kinase inhibitor (TKI) of fibroblast growth factor receptor (FGFR) that is approved by the FDA to treat...

Full description

Bibliographic Details
Main Authors: Weiguo Feng, Meng Zhang, Zhuo-Xun Wu, Jing-Quan Wang, Xing-Duo Dong, Yuqi Yang, Qiu-Xu Teng, Xuan-Yu Chen, Qingbin Cui, Dong-Hua Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Oncology
Subjects:
erdafitinib
ABCB1
multidrug resistance
reversal effect
cancer
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00955/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00955/full

Similar Items